Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics, Inc. was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.

Century Therapeutics, Inc.

Century Therapeutics focuses on developing allogeneic, iPSC-derived NK and T cell therapies for the treatment of cancer and autoimmune diseases.

Metric
Company Name	Century Therapeutics, Inc.
Symbol	IPSC
MSH ID	COM:CENTURYTX
Market	STOCKS
Sector	Healthcare
Industry	Biotechnology
Country	US
Stage
Employee Count	152
Website	centurytx.com
LinkedIn
Founders

Metric
Market Cap	199.42M
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	2.23M
Revenue (LTM)
Revenue (NTM)
Gross Profit	-10.81M
EBITDA	-112.14M
Operating Income	-125.18M
Net Income	-136.67M
EPS	-2.30
Diluted EPS	-2.30
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	-3.19
Operating Profit Margin	-59.69
EBITDA Margin	-50.17
Net Profit Margin	-61.15
Return on Equity	-0.59
Return on Assets	-0.32
Return on Capital Employed	-0.33

COM:CENTURYTX

Century Therapeutics

Last Close

1.24

22/11 21:00

Market Cap

199.42M

Beta: -

Volume Today

511.90K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-1.92
P/B Ratio	1.13
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	203.39
EV Multiple	-0.89

Metric
Days Sales Outstanding	244.26
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle	314.41
Cash Conversion Cycle	212.50
Asset Turnover	0.01

Metric
Operating Cash Flow	-88.57M
Free Cash Flow	-102.30M
Cash Flow to Debt	-1.33
Operating Cash Flow/Sales	-34.34
Free Cash Flow Yield	-0.42

Metric
Cash & Equivalents	47.32M
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization	0.21
Debt to Assets	0.12
Current Ratio	8.50
Quick Ratio	12.44

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	5.54
R&D to Revenue	38.58
SG&A to Revenue	13.81